The financials
Viridian Therapeutics, Inc. by the numbers
Viridian Therapeutics, Inc. (VRDN) reported revenue of $284K in Q2 2026 (quarter ended Jun 30, 2026), up 279% from the same quarter a year earlier. That came with net loss of $127M. For the full year FY2025, revenue was $71M (+23360% year on year) and net income −$343M. Its largest product in Q2 2026 was License at $233K, 82% of the disclosed total, well ahead of Collaboration at 18%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $284K | $75K | +279% |
| Operating income | −$126M | −$107M | n/a |
| Net income | −$127M | −$101M | n/a |
| Diluted EPS | n/a | −$1.23 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License | $233K | 82% |
| Collaboration | $51K | 18% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $284.0K (+101%)
Collaboration grew -32% year on year
Segment Latestquarter on quarteryear on year
- License$233.0K$233.0KQoQ +3783%year on year -+3783%-
- Collaboration$51.0K$51.0KQoQ -62%year on year -32%-62%-32%